<DOC>
	<DOCNO>NCT02562287</DOCNO>
	<brief_summary>The clinical use clozapine unequivocal advance treatment schizophrenia , chronic severe mental illness . A wealth clinical data demonstrate offer enhance efficacy positive negative symptomatology , improve cognition , function quality life . It also associate improved compliance continue efficacy long-term treatment translate reduction suicidality all-cause mortality . Because preclinical evidence modulates neuroplasticity prefrontal cortex connectivity , clozapine may interest strategy severe psychotic illness . Nevertheless , even consider grow use atypical antipsychotic management bipolar disorder , role clozapine poorly define . The clinical evidence-base use condition largely base uncontrolled naturalistic trial retrospective study chart review . Several support clozapine 's efficacy treatment-resistant bipolar disorder . Possibly clozapine 's profile adverse effect lack interest pharmaceutical company , two randomized trial examine effectiveness . Both suggest clinically relevant antimanic mood-stabilizing property . Therefore , primary objective trial determine effectiveness clozapine treatment-resistant bipolar disorder . Secondary objective include examine effect treatment clozapine cognition function patient bipolar disorder . Tolerability safety long-term clozapine use also examine . To end , investigator conduct clinical trial 54 patient history treatment resistance . Patients randomize either open-label treatment clozapine , combination lithium valproate , open-label treatment atypical antipsychotic consistent evidence efficacy treatment bipolar disorder ( olanzapine , quetiapine risperidone ) , also combination lithium valproate . Patients follow one-year time all-cause treatment failure primary outcome measure . It belief investigator study generate meaningful clinical data tremendous importance validate clozapine legitimate treatment option treatment-resistant bipolar disorder .</brief_summary>
	<brief_title>Clozapine Versus Other Atypical Antipsychotics Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>DSMIV Bipolar I Disorder ; mood episode within precede year ; DSMIV rapid cyclers permit participate study ; male females 18 65 year age ; ongoing illness symptom include significant functional impairment ; document history treatment resistance , define persistent symptom despite simultaneous , adequate treatment least two medication : one mood stabilizer ( lithium valproate ) + antipsychotic OR two mood stabilizer ( least one lithium valproate ) . patient must level understanding sufficient agree test require protocol must sign informed consent document patient onset illness age 40 illness result secondary cause woman pregnant breastfeeding , use adequate contraception unstable medical illness clinically significant abnormal laboratory test current active alcohol substance abuse severe personality disorder contraindication use clozapine previous treatment clozapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>